Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes off patent in 2023.

Merck also highlighted China as a key growth driver and provided insight into its appetite for M&A.

"Everything we need to drive growth through Januvia patent expiry is in our hands and now it's really about executing in the market and in the development space to make sure we can maintain our leadership," said

Read the full 915 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers